SANTA MONICA, Calif. - GoodRx Holdings, Inc. (NASDAQ:GDRX), a leading U.S. prescription savings platform, announced the appointment of Scott Wagner as Co-Chair of its Board of Directors, effective January 21, 2025. Wagner, who served as the company’s Interim CEO from April 2023 until his recent appointment, brings over 25 years of executive leadership experience to the role. The appointment comes as GoodRx maintains impressive gross profit margins of 94% and analysts expect positive net income growth this year, according to InvestingPro data.
Wagner’s previous roles include CEO and other executive positions at GoDaddy (NYSE:GDDY), where he was instrumental in the company’s global expansion and revenue growth. He also served as a Partner at global investment firm KKR. His tenure at GoodRx as Interim CEO has been marked by efforts to shape the company’s strategic direction. InvestingPro analysis reveals the company operates with moderate debt levels and maintains strong liquidity, with current assets well exceeding short-term obligations.
Trevor Bezdek, co-founder and existing Co-Chair of GoodRx, expressed enthusiasm for Wagner’s new role, citing his deep understanding of the company’s business and his potential to influence its growth and innovation.
In addition to his co-chair responsibilities, Wagner will chair the Board’s Compensation Committee. His appointment coincides with the resignation of Simon Patterson, who stepped down from his directorship and membership in the Board’s Nominating and Corporate Governance Committee and Innovation Committee on the same date.
GoodRx is known for providing medication cost savings and healthcare information to millions of Americans. It has been credited with saving consumers over $75 billion on prescription costs since its inception in 2011.
The company encourages investors and potential investors to follow its press releases, SEC filings, and public communications, which are periodically updated on its investor relations website.
This announcement is based on a press release statement from GoodRx Holdings, Inc.
In other recent news, GoodRx has seen substantial changes in its executive team, with CFO Karsten Voermann resigning for personal reasons. Romin Nabiey, the current Chief Accounting Officer, will serve as interim CFO. Analyst Michael Cherny from Leerink maintains a positive outlook on GoodRx despite the abrupt resignation, highlighting the company’s Ebitda and cash flow generation.
In a related development, Wendy Barnes, formerly CEO of RxBenefits, has taken the helm as GoodRx’s new CEO. Barnes’ appointment has been met with optimism from Wells Fargo (NYSE:WFC) analyst Stan Berenshteyn, who reiterated an Overweight rating on GoodRx.
Despite these positive developments, Raymond (NSE:RYMD) James has removed GoodRx from its Analyst Favorites list, citing a need for more time for the company’s turnaround initiatives to show visible financial improvements. Similarly, Mizuho (NYSE:MFG) initiated coverage on GoodRx with a Neutral rating, projecting the company’s 2026 revenue at $860 million, which falls short of GoodRx’s target of approximately $1 billion.
Sarah Griffis, a former leader at GoodRx, has been appointed as the new Chief Technology Officer at WM Technology, known for operating the cannabis marketplace Weedmaps. These are among the recent developments for GoodRx, reflecting a period of significant transition and strategic shifts within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.